Rein Therapeutics (015A) Ratios
Rein Therapeutics Ratios
DE:015A's free cash flow for Q2 2026 was $-8.64M. For the 2026 fiscal year, DE:015A's free cash flow was increased by $0.00 and operating cash flow was $-8.64M. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.70 | 2.38 | 4.17 | 6.46 | 10.69 |
| Quick Ratio | 0.70 | 2.38 | 4.17 | 6.46 | 10.69 |
| Cash Ratio | 0.52 | 2.24 | 3.95 | 1.53 | 0.80 |
| Solvency Ratio | -6.89 | -4.23 | -0.00 | -0.01 | -0.01 |
| Operating Cash Flow Ratio | -3.13 | -3.88 | -4.52 | -7.35 | -5.27 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ -2.91M | $ -1.19M | $ -80.86M | $ 18.49M | $ 43.60M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.43 | 1.27 | 15.39 | 1.18 | 1.10 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.01 | 0.01 | 0.04 |
| Net Debt to EBITDA | 0.06 | 0.46 | 1133.69 | 187.82 | 129.81 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 98.59% | 97.78% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 230.65% | 98.77% | 96.66% | 98.85% | 98.34% |
| Return on Assets (ROA) | -206.44% | -90.82% | -0.01% | -0.12% | -0.05% |
| Return on Equity (ROE) | -294.78% | -115.61% | -0.23% | -0.15% | -0.06% |
| Return on Capital Employed (ROCE) | -121.99% | -102.55% | -0.02% | -0.15% | -0.06% |
| Return on Invested Capital (ROIC) | -120.27% | -100.09% | -0.02% | -0.15% | -0.06% |
| Return on Tangible Assets | -1152.29% | -303.64% | -0.08% | -0.12% | -0.05% |
| Earnings Yield | -168.96% | -152.42% | -0.16% | -0.28% | -0.28% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1451240.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 1451240.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.76 | -1.24 | -4.31 | -5.48 | -5.35 |
| Free Cash Flow Per Share | -0.76 | -1.24 | -4.31 | -5.48 | -5.39 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -151.30 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -151.30 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | -412.67 | -753.48 | -146.63 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -65.60% | -54.03% | -203.21% | -258.40% | -254.03% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.59 | -0.66 | -619.61 | -352.11 | -359.76 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 1.74 | 0.76 | 1.42 | 0.52 | 0.21 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.52 | -1.85 | -0.49 | -0.39 | -0.39 |
| Price-to-Operating Cash Flow Ratio | -1.52 | -1.85 | -0.49 | -0.39 | -0.40 |
| Price-to-Earnings Growth (PEG) Ratio | 0.01 | -0.25 | 14.35 | -159.53 | -0.00 |
| Enterprise Value Multiple | -0.52 | -1.01 | 493.61 | -162.37 | -225.60 |
| Enterprise Value | 26.30M | 28.39M | -7.52M | 4.46M | 5.97M |
| EV to EBITDA | -0.52 | -1.01 | 493.61 | -162.37 | -225.60 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -1.36 | -1.27 | 0.38 | -0.18 | -0.25 |
| EV to Operating Cash Flow | -1.36 | -1.27 | 0.38 | -0.18 | -0.25 |
| Tangible Book Value Per Share | -0.11 | 0.33 | -17.10 | 4.10 | 9.89 |
| Shareholders’ Equity Per Share | 0.66 | 3.03 | 1.50 | 4.10 | 9.89 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.01 | 0.02 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -1.96 | -3.51 | -0.00 | -0.01 | -0.01 |
| Tax Burden | 0.99 | 0.98 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 2.29 | 1.03 | 0.99 | 0.98 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.39 | 0.35 | 1.26 | 0.91 | 0.91 |
Currency in USD